Real World Evidence Solutions: An Emerging Market with Attractive Growth Opportunities

04.10.2019 - 14:53 | 1759392

Artikel von marketsandmarkets

Real World Evidence Solutions Market by Component (Dataset, (Claims, Clinical, Pharmacy, Patient), Services), Therapeutic Area (Oncology, Cardiovascular, Immunology), End User (Pharmaceuticals, Medical Devices, Payers, Providers) - Global Forecast to 2023

According to the new market research “Real World Evidence Solutions Market  by Component (Dataset (Claims, Clinical, Pharmacy, Patient), Services), Therapeutic Area (Oncology, Cardiovascular, Immunology), End User (Pharmaceuticals, Medical Devices, Payers, Providers) - Global Forecast to 2023", analyzes and studies the major market drivers, restraints/challenges, and opportunities. The global real-world evidence market is valued at 612.0 million in 2017 and projected to reach USD 1,348.1 million by 2023, at a CAGR of 14.3%. 

The global Real World Evidence Solutions market is segmented based on component, therapeutic area, end user and regions

On the basis of component, the data sets segment accounted for the largest share of the global real world evidence market. The large share can be attributed to factors such as easy availability of massive amounts of data, increasing dependence of outcome-based studies on real-world data, and rising demand for information by payers and providers regarding drug safety.

Download a PDF Brochure:-

Browse and in-depth TOC on in “Real World Evidence Solutions Market " 
92 - Tables
40 - Figures 
157 - Pages 

Based on therapeutic area, the oncology segment accounted for the largest share of the real-world evidence market in 2017. The large share of this segment can be attributed to the high number of clinical trials conducted for oncology and the rising prevalence of cancer worldwide.

Based on end user, the pharmaceutical & medical device companies segment accounted for the largest share of the real world evidence market. The large share of this segment can be attributed to the increasing importance of RWE studies in drug approvals, the need to prevent costly drug recalls, and the increasing need to assess drug performance in real-world settings.

Request Free Sample Report (at)

North America accounted for the largest share of the real world evidence market in 2017, followed by Europe and Asia Pacific. Presence of a favorable regulatory environment, high number of RWE service providers, the presence of a well-established pharmaceutical industry in the region, coupled with the high R&D expenditure, are the major factors responsible for the large share of North America in the global real world evidence market.

Market Players

The key players in the Real World Evidence Solutions market are  IQVIA (US), ICON (Ireland), PAREXEL (US), Pharmaceutical Product Development (US), Optum (US), International Business Machines Corporation (US), Cognizant (US), Oracle (US), SAS (US), Syneos Health (US), Anthem (US), Clinigen Group (UK), Palantir Technologies (UK), and Flatiron Health (US).

View Complete Press Release (at)

Unternehmensinformation / Kurzprofil:

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, and strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.


PresseKontakt / Agentur:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
Email: sales(at)


Vor- / Nachname: marketsandmarkets

Ansprechpartner: Mr. Shelly Singh
Stadt: northbrook
Telefon: 8886006441

Keywords (optional):
real-world-evidence-solutions-market, global-real-world-evidence-solutions-market, real-world-evidence-solutions, real-world-evidence-solutions-market-size, real-world-evidence-solutions-market-forecast, real-world-evidence-solutions-market-insights, real,

Dieser Artikel wurde bisher 67 mal aufgerufen.


Direkter Link zu diesem Artikel:

Diese Pressemeldung bookmarken bei...

Tausendreporter BlinkList Folkd Furl Google Linkarena Mister Wong oneview Yahoo MyWeb YiGG Webnews Technorati

Über einen Link auf Ihrer News-, Presse- oder Partner-Seite würden wir uns sehr freuen.

Hiermit versichert der Erfasser, dass der eingestellte Artikel der Wahrheit entspricht. Er ist frei von Rechten Dritter und steht zur Veröffentlichung bereit. Die Haftung für eventuelle Folgen (z.B. Abmahnungen, Schadenersatzforderungen etc.) übernimmt der Eintrager und nicht

[ Anfrage per Mail | Fehlerhaften Artikel melden | Druckbare Version | Diesen Artikel an einen Freund senden ]

Alle Artikel von marketsandmarkets RSS Feed

Sai Life Sciences gibt Sai Nxt bekannt, Transformationsinitiative der Organisation in eine CDMO der neuen Generation
AGC Biologics erweitert Leistungsangebot bei Plasmid-DNA
IDF Congress 2019: Biocon Biologics-Symposium zu ''100 Jahre Insulin - mit Entschlossenheit für eine flächendeckende& gerechte Versorgung'' kommt bei führenden Meinungsbildern gut an
First-in-Human-Daten Veröffentlicht: Sicherheit und Wirksamkeit von Tigilanol Tiglat bei soliden Tumoren
Keeogo(TM) darf CE-Kennzeichnung tragen - Keeogo(TM) des Herstellers B-Temia darf CE-Kennzeichnung tragen, kann in Ländern der EU vertrieben werden

Blogverzeichnis - Blog Verzeichnis bloggerei.deBlog Top Liste - by